- Home
- CNM vs ROIV Comparison
CNM vs ROIV Comparison
Compare CNM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNM
- ROIV
- Stock Information
- Founded
- CNM 1996
- ROIV 2014
- Country
- CNM United States
- ROIV United Kingdom
- Employees
- CNM N/A
- ROIV N/A
- Industry
- CNM Durable Goods
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CNM Consumer Discretionary
- ROIV Health Care
- Exchange
- CNM Nasdaq
- ROIV Nasdaq
- Market Cap
- CNM 9.9B
- ROIV 8.6B
- IPO Year
- CNM 2021
- ROIV N/A
- Fundamental
- Price
- CNM $51.32
- ROIV $19.86
- Analyst Decision
- CNM Buy
- ROIV Strong Buy
- Analyst Count
- CNM 11
- ROIV 8
- Target Price
- CNM $60.64
- ROIV $21.06
- AVG Volume (30 Days)
- CNM 2.0M
- ROIV 8.1M
- Earning Date
- CNM 12-02-2025
- ROIV 11-10-2025
- Dividend Yield
- CNM N/A
- ROIV N/A
- EPS Growth
- CNM 7.24
- ROIV N/A
- EPS
- CNM 2.25
- ROIV N/A
- Revenue
- CNM $7,740,000,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CNM $4.45
- ROIV N/A
- Revenue Next Year
- CNM $4.43
- ROIV $320.50
- P/E Ratio
- CNM $22.89
- ROIV N/A
- Revenue Growth
- CNM 11.02
- ROIV N/A
- 52 Week Low
- CNM $41.64
- ROIV $8.73
- 52 Week High
- CNM $67.18
- ROIV $20.09
- Technical
- Relative Strength Index (RSI)
- CNM 42.04
- ROIV 79.61
- Support Level
- CNM $50.03
- ROIV $19.30
- Resistance Level
- CNM $54.02
- ROIV $20.09
- Average True Range (ATR)
- CNM 1.47
- ROIV 0.57
- MACD
- CNM 0.10
- ROIV 0.11
- Stochastic Oscillator
- CNM 23.79
- ROIV 92.97
About CNM Core & Main Inc.
Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.